Drug Interaction Study of SAR302503 in Patients With Solid Tumor

Solid Tumor Clinical Trial

Official title:

An Open-label, Two-treatment Crossover Pharmacokinetic Interaction Study of Repeated Doses of SAR302503 on Pharmacokinetics of a Single Dose Cocktail of Omeprazole, Metoprolol, and Midazolam Used as Probe Substrates for CYP2C19, CYP2D6 and CYP3A4 Activities, Respectively in Adult Patients With Refractory Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01585623
• Other study ID #: INT12497
• Secondary ID: U1111-1125-8930
• Status: Completed
• Phase: Phase 1
• First received: April 13, 2012
• Last updated: March 21, 2013
• Start date: June 2012
• Est. completion date: March 2013

Study information

• Verified date: March 2013
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Primary Objective:

• To assess the effect of 15-day repeated oral doses of 500 mg SAR302503 on the cytochrome P450 activity using a CYP probe cocktail (2C19, 2D6 and 3A4).

• To document pharmacokinetics of SAR302503 after repeated 500 mg oral daily doses.

Secondary Objectives:

• To assess the safety profile of 15-day repeated oral doses of 500 mg SAR302503 in Segment 1

• To characterize the safety and tolerability of 28-day consecutive doses of 500 mg SAR302503 in Segment 2

• To determine antitumor activity in Segment 2

Description:

The duration of the study for an individual patient will include a period to assess eligibility (screening period 21 days), followed by a treatment period of at least 15 days of study treatment, and an end-of-treatment visit at least 30 days following the last administration of study drug. However, treatment may continue if patients are receiving benefit and do not have unacceptable toxicity or meet study withdrawal criteria.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: March 2013
• Est. primary completion date: March 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion criteria :

• Histologically or cytologically confirmed advanced solid malignancy that is metastatic or unresectable, and for which standard curative measures do not exist

• Signed informed consent

Exclusion criteria:

• Less than 18 years of age.

• Limited physical functioning (as evaluated by the Eastern Cooperative Oncology Group (ECOG) scale)

• Inability to follow study requirements and schedule

• Treatment of cancer within 3 weeks of study, concurrent treatment in another clinical trial or with any other anti-cancer therapy

• Serious medical illness at same time of study and/or significantly abnormal lab reports

• Lack of pregnancy contraception (women of childbearing potential), pregnancy, or breast feeding.

• Men who partner with a woman of childbearing potential, unless they agree to use effective contraception while on study drug

• Continued toxic effects of prior chemotherapy

• Evidence of other concurrent active malignancy

• Other concurrent serious illness or medical condition

• Cardiac abnormalities include bradycardia, AV block or other conduction defect on ECG, and patients taking a beta blocker.

• Patients with Insulin-Dependent Diabetes Mellitus.

• Patients with known active (acute or chronic) hepatitis A, B, C, and hepatitis B and C carries. Prior history of chronic liver disease (e.g., chronic alcoholic liver disease, autoimmune hepatitis, sclerosing cholangitis, primary biliary cirrhosis, hemachromatosis, non-alcoholic steatohepatitis [NASH]).

• Inadequate organ function

• History of partial or total gastrectomy, or, if in the opinion of the investigator, have any other disorder that would inhibit absorption of oral medications.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Solid Tumor

Intervention

Drug:
• SAR302503
Pharmaceutical form:capsule Route of administration: oral
• omeprazol
Pharmaceutical form:capsule Route of administration: oral
• metoprolol
Pharmaceutical form:tablet Route of administration: oral
• midazolam
Pharmaceutical form:solution Route of administration: oral

Locations

Country	Name	City	State
United States	Investigational Site Number 840004	Augusta	Georgia
United States	Investigational Site Number 840001	Detroit	Michigan
United States	Investigational Site Number 840002	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Omerprazole/metoprolol/midazolam - Pharmacokinetic parameter: AUC, AUClast		predose and up to 24 hours post dose on Days -1, 1, 15 and 16	No
Secondary	Omerprazole/metoprolol/midazolam - Pharmacokinetic parameter : Cmax, Tmax, and t1/2z		predose and up to 24 hours post dose on Days -1, 1, 15 and 16	No
Secondary	SAR302503 - Pharmacokinetic parameter : Cmax, Tmax, Ctrough and AUC0-24		Day-1 to Day 16	No
Secondary	Clinical and laboratory events graded by the NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) v4.03 (Segment 1 and 2)		up to maximum 2 years	No
Secondary	Objective response ratio (Complete response (CR) and partial response (PR)) (Segment 2)		up to 2 cycles ( i.e. 10 weeks)	No